基本信息
楼丽广 男 博导 上海药物研究所
电子邮件：lglou@mail.shcnc.ac.cn
通信地址：上海市浦东张江祖冲之路555号
邮政编码：201203
电子邮件：lglou@mail.shcnc.ac.cn
通信地址：上海市浦东张江祖冲之路555号
邮政编码：201203
招生信息
招生专业
100706-药理学
071020-生物技术与医药
071020-生物技术与医药
招生方向
肿瘤药理
抗肿瘤药物发现和研制
抗肿瘤药物发现和研制
教育背景
2000-03--2002-06 University of Pittsburgh, USA 药理学，博士后
1996-09--1998-07 中国科学院细胞生物学研究所 细胞生物学，博士后
1993-09--1996-07 中国科学院上海药物研究所 药理学，博士
1990-10--1993-07 河南医科大学 药理学，硕士
1982-09--1985-07 浙江省金华卫生学校 医士
1996-09--1998-07 中国科学院细胞生物学研究所 细胞生物学，博士后
1993-09--1996-07 中国科学院上海药物研究所 药理学，博士
1990-10--1993-07 河南医科大学 药理学，硕士
1982-09--1985-07 浙江省金华卫生学校 医士
学历
-- 研究生
学位
-- 博士
工作经历
工作简历
1998-08--今 中国科学院上海药物研究所 副研究员，研究员
1985-08--1990-07 浙江衢州卫生学校 教员
1985-08--1990-07 浙江衢州卫生学校 教员
专利与奖励
奖励信息
（1） 全国优秀博士后，一等奖，国家，2005
（2） 明治乳业生命科学奖，一等奖，院级，1998
（3） “国氏”博士后奖励基金，一等奖，国家，1998
（4） 上海市优秀博士后，一等奖，省，1998
（2） 明治乳业生命科学奖，一等奖，院级，1998
（3） “国氏”博士后奖励基金，一等奖，国家，1998
（4） 上海市优秀博士后，一等奖，省，1998
专利成果
[1] 胡有洪, 楼丽广, 谢志铖, 李琳, 王蕾. 一类含杂芳环炔基化合物及其制备方法和用途. 202310214944.8, 2023-03-08.[2] 黄蔚, 楼丽广, 董乾, 童梦雅, 敖继炜, 全海天, 蒋柏凤. 一类含糖结构化合物、其制备方法、药物组合物和用途. CN: CN113943330A, 2022-01-18.[3] 杨伟波, 楼丽广, 许忠良, 全海天, 宋必超. 一种多取代1,3-二烯支撑的环化合物及其用途. CN: CN112898213A, 2021-06-04.[4] 杨伟波, 楼丽广, 许忠良, 全海天, 陈露. 一种烯丙基醇支撑的大环内酯化合物及其用途. CN: CN112898224A, 2021-06-04.[5] 岳建民, 楼丽广, 刘翠萍, 谢成英, 纪开龙, 赵金鑫. 一个具有逆转肿瘤多药耐药活性的新骨架环脂肽化合物、其制备方法及用途. CN: [[[CN111689923A]]], [[["2020-09-22"]]].[6] 刘伟平, 楼丽广, 侯树谦, 高安丽, 谢成英, 全海天, 姜婧. 以磷酸二氢根为轴向配体的铂(IV)抗癌化合物. CN: CN105481902A, 2016-04-13.[7] 刘伟平, 楼丽广, 姜婧, 侯树谦, 叶青松, 常桥稳. 肝靶向铂类抗癌药物及其合成方法. CN: CN104610415A, 2015-05-13.[8] 刘伟平, 楼丽广, 侯树谦, 孙丽萍, 姜婧, 谢成英, 叶青松. 以3-氧代-环丁烷-1,1-二羧酸根为配体的铂(II)抗肿瘤化合物. CN: CN104086597A, 2014-10-08.[9] 刘伟平, 楼丽广, 谌喜珠, 谢成英, 姜婧, 叶青松, 全海天, 常桥稳. 洛铂的一种水溶性、稳定衍生物. CN: CN103772435A, 2014-05-07.[10] 胡有洪, 楼丽广, 陈红, 全海天, 李德文, 谢成英. 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途. CN: CN104341386A, 2015-02-11.[11] 楼丽广, 李援朝, 姜标, 陈红莉, 施晶晶, 杜娟娟. 含有24-表油菜素内酯和24-异表油菜素内酯的组合物作为雄激素受体调节剂的用途. CN: CN103768074A, 2014-05-07.[12] 楼丽广, 胡有洪, 赵红兵, 林世军, 谢成英, 邢唯强, 全海天, 李德文. 6-(4-(二氟甲氧基)-3-甲氧基苯基)哒嗪-3(2H)-酮在制备抗肿瘤药物中的用途. CN: CN102872017A, 2013-01-16.[13] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代含氟苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443040A, 2012-05-09.[14] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443043A, 2012-05-09.[15] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代含甲氧基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443042A, 2012-05-09.[16] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代含甲基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443041A, 2012-05-09.[17] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代含酯基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443044A, 2012-05-09.[18] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代氨基苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443039A, 2012-05-09.[19] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英, 李征. N-取代苯基-14β-氨甲基表雷公藤内酯醇衍生物及其制备方法和用途. CN: CN102443045A, 2012-05-09.[20] 刘伟平, 楼丽广, 谌喜珠, 谢成英, 叶青松, 全海天. 一种水溶性S,S-型庚铂衍生物. CN: CN102079761A, 2011-06-01.[21] 李援朝, 楼丽广, 周兵, 王蕾, 杨亚玺, 全海天, 冯慧瑾, 谢成英. 新型松香烷型二萜衍生物、其制备方法和应用. CN: CN102286065A, 2011-12-21.[22] 楼丽广, 刘伟平, 谌喜珠, 全海天, 叶青松, 侯树谦, 谢成英. 含有二氯乙酰氧基的铂(II)类抗癌配合物. CN: CN101914117A, 2010-12-15.[23] 胡有洪, 楼丽广, 林世军, 赵红兵, 邢唯强, 全海天. 一类以N为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途. CN: CN102133217A, 2011-07-27.[24] 胡有洪, 楼丽广, 谢福春, 赵红兵. 一类嘧啶类小分子化合物、其制备方法及用途. CN: CN102115470A, 2011-07-06.[25] 胡有洪, 楼丽广, 刘杨, 吴琼, 黄丽平, 谢成英. 一类多环苯并吡喃酮类化合物及其制备方法和用途. CN: CN102108083A, 2011-06-29.[26] 刘伟平, 楼丽广, 谢明进, 谌喜珠, 叶青松, 余尧, 常桥稳, 侯树谦. 一种水溶性羧桥双核Pt(Ⅱ)抗肿瘤配合物. CN: CN101787051A, 2010-07-28.[27] 胡有洪, 楼丽广, 林世军, 赵红兵, 刘振德, 徐永平, 晁博. 一类哒嗪酮类化合物及其制备方法和制备药物的用途. CN: CN101538245B, 2011-02-16.[28] 胡有洪, 楼丽广, 林世军, 赵红兵, 刘振德, 徐永平, 晁博. 哒嗪酮类化合物在制备抗肿瘤药物中的用途. CN: CN101537006A, 2009-09-23.[29] 刘伟平, 楼丽广, 谌喜珠, 侯树谦, 叶青松, 余尧. 以3-乙酰氧基-1,1-环丁烷二羧酸根为离去基团的水溶性Pt(II)抗癌配合物. CN: CN101386629B, 2011-06-29.[30] 李明宗, 楼丽广, 尤田耙, 唐卫东, 金炜, 王欣. 一种7－位环烷基取代的喜树碱衍生物及合成方法和用途. CN: CN101376658A, 2009-03-04.[31] 刘伟平, 楼丽广, 谌喜珠, 叶青松, 侯树谦, 余尧. 一种新型的奥沙利铂衍生物. CN: CN101289468A, 2008-10-22.[32] 刘伟平, 楼丽广, 谌喜珠, 侯树谦, 叶青松, 余尧. 一种新型的水溶性铂(Ⅱ)小分子抗癌配合物. CN: CN101134601A, 2008-03-05.[33] 黄成钢, 马春辉, 丁健, 楼丽广, 孙兆林, 唐意红, 李志雄, 范明松. 从中药王不留行中分离获得的三萜类化合物及它们的用途. CN: CN101333238A, 2008-12-31.[34] 胡有洪, 楼丽广, 程刚, 徐永平, 谢福春, 唐卫东, 李佳. 一类新型嘧啶类小分子化合物、其制备方法及其用途. CN: CN101033224B, 2011-04-27.[35] 胡立宏, 沈旭, 蒋华良, 楼丽广, 丁宏, 邵勇, 章涵堃. 长春碱衍生物、其制备方法和用途、以及包含该衍生物的药物组合物. CN: CN101235046B, 2010-09-08.[36] 胡立宏, 沈旭, 蒋华良, 楼丽广, 丁宏, 邵勇, 章涵堃. 新的长春碱衍生物、其制备方法和用途、以及包含该衍生物的药物组合物. CN: CN101235046A, 2008-08-06.[37] 刘伟平, 楼丽广, 谌喜珠, 侯树谦, 李永年. 以2－羟基－1,3－丙二胺为载体基团的铂(Ⅱ)抗癌配合物. CN: CN1948323A, 2007-04-18.[38] 刘伟平, 楼丽广, 侯树谦, 李永年, 叶青松, 余尧, 谌喜珠. 亲脂性铂类抗肿瘤配合物. CN: CN1923837A, 2007-03-07.[39] 李援朝, 楼丽广, 邓刚, 徐永平, 冯慧瑾, 唐卫东. 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用. CN: CN101049300A, 2007-10-10.[40] 张金生, 昌军, 楼丽广, 唐卫东. 20(S)－喜树碱衍生物、其制备方法及用途. CN: CN1580057A, 2005-02-16.[41] 穆青, 楼丽广, 郝小江, 唐卫东, 李朝明, 徐永平, 孙汉董, 钟利, 胥彬. 抗癌药物及其制备方法. 中国: CN1377646, 2002-11-06.[42] 穆青, 唐卫东, 李朝明, 胥彬, 孙汉董, 楼丽广, 郑惠兰. 7－表－哥纳香二醇及其衍生物. CN: CN1266060A, 2000-09-13.[43] 杨伟波, 楼丽广, 许忠良, 全海天, 陈露. 一种烯丙基醇支撑的大环内酯化合物及其用途. CN: CN112898224B, 2023-02-17.
出版信息
发表论文
[1] 楼丽广. Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug Resistance.. J Med Chem[J]. 2024, 第 1 作者 通讯作者 67(6): 4560-4582, [2] 楼丽广. SIBP-03, a novel anti-HER3 antibody, exerts antitumor effects and synergizes with EGFR- and HER2-targeted drugs. Acta Pharmacologica Sinica[J]. 2024, 第 1 作者 通讯作者 45(4): 857-866, [3] Dong, Qian, Tong, Mengya, Yu, Xiaolu, Wang, Lei, Ao, Jiwei, Guan, Dongliang, Tang, Yubo, Liu, Junjie, Long, Li, Tong, Yongliang, Fang, Shanhua, Zhou, Hu, Huang, Yongzhuo, Gong, Likun, Lou, Liguang, Huang, Wei. Carbohydrate Strengthens the Immunotherapeutic Effect of Small-Molecule PD-L1 Inhibitors. JOURNAL OF MEDICINAL CHEMISTRY[J]. 2023, 第 15 作者 通讯作者 66(11): 7179-7204, http://dx.doi.org/10.1021/acs.jmedchem.2c01347.[4] Liu, Bo, Yu, Xueni, Liu, Liping, Wang, Lei, Wang, Jie, Huang, Qianqian, Xu, Zhongliang, Luo, Cheng, Lou, Liguang, Huang, Wei, Yang, Weibo. Modular Biomimetic Strategy Enabled Discovery of Simplified Pseudo-Natural Macrocyclic P-Glycoprotein Inhibitors Capable of Overcoming Multidrug Resistance. JOURNAL OF MEDICINAL CHEMISTRY[J]. 2023, 第 9 作者 通讯作者 66(4): http://dx.doi.org/10.1021/acs.jmedchem.2c01424.[5] Li, Yongpeng, Li, Lin, Fu, Haoyu, Yao, Qing, Wang, Lei, Lou, Liguang. Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers. AMERICAN JOURNAL OF CANCER RESEARCH[J]. 2023, 第 6 作者 通讯作者 13(1): 161-+, http://apps.webofknowledge.com/CitedFullRecord.do?product=UA&colName=WOS&SID=5CCFccWmJJRAuMzNPjj&search_mode=CitedFullRecord&isickref=WOS:000950570900009.[6] Zhicheng Xie, Lin Li, Yihao Guo, Mi Zhang, Taiwen Chen, Yongpeng Li, Xin Li, Xi Zhu, Yu Zhang, Liguang Lou, Youhong Hu. Discovery of novel heteroaryl alkynes for highly potent KIT^(D816V) cells inhibition to treat gastrointestinal stromal tumors. 药学学报:英文版[J]. 2022, 第 10 作者12(10): 4004-4007, http://lib.cqvip.com/Qikan/Article/Detail?id=7108535207.[7] Xu, Piaopiao, Chen, Xiangling, Xu, Yongping, Fu, Li, Li, Yun, Fu, Haoyu, Yao, Qing, Quan, Haitian, Lou, Liguang. Trastuzumab in combination with PEGylated interferon-alpha 1b exerts synergistic antitumor activity through enhanced inhibition of HER2 downstream signaling and antibody-dependent cellular cytotoxicity. AMERICAN JOURNAL OF CANCER RESEARCH[J]. 2022, 第 9 作者 通讯作者 12(2): 549-561, http://apps.webofknowledge.com/CitedFullRecord.do?product=UA&colName=WOS&SID=5CCFccWmJJRAuMzNPjj&search_mode=CitedFullRecord&isickref=WOS:000765695800007.[8] Yang, GuanZhou, Wang, Lei, Fan, YaoYue, Lai, ZengWei, Yu, XueNi, Lou, LiGuang, Gao, Kun, Yue, JianMin. Concise Total Synthesis of Dysoxylactam A and a Simplified Analog. CHINESE JOURNAL OF CHEMISTRY[J]. 2022, 第 6 作者40(17): 2027-2034, http://dx.doi.org/10.1002/cjoc.202200123.[9] Wang, Lei, Zhu, Xi, Li, Lili, Li, Lin, Fu, Li, Li, Yun, Fu, Haoyu, Chen, Xiaoyan, Lou, Liguang. TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. AMERICAN JOURNAL OF CANCER RESEARCH[J]. 2021, 第 9 作者 通讯作者 11(4): 1632-1645, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085876/.[10] Zhang, Mi, Quan, Haitian, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang. Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. THORACIC CANCER[J]. 2021, 第 6 作者 通讯作者 12(8): 1210-1218, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046080/.[11] Song, Bichao, Xie, Peipei, Li, Yingzi, Hao, Jiping, Wang, Lu, Chen, Xiangyang, Xu, Zhongliang, Quan, Haitian, Lou, Liguang, Xia, Yuanzhi, Houk, K N, Yang, Weibo. Pd-Catalyzed Decarboxylative Olefination: Stereoselective Synthesis of Polysubstituted Butadienes and Macrocyclic P-glycoprotein Inhibitors. JOURNALOFTHEAMERICANCHEMICALSOCIETY[J]. 2020, 第 9 作者142(22): 9982-9992, https://www.webofscience.com/wos/woscc/full-record/WOS:000538526500014.[12] Wang, Lei, Wang, Quanren, Xu, Piaopiao, Fu, Li, Li, Yun, Fu, Haoyu, Quan, Haitian, Lou, Liguang. YES1amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer. BRITISH JOURNAL OF CANCER[J]. 2020, 第 8 作者 通讯作者 123(6): 1000-1011, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494777/.[13] Chen, Lu, Quan, Haitian, Xu, Zhongliang, Wang, Hao, Xia, Yuanzhi, Lou, Liguang, Yang, Weibo. A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation. NATURE COMMUNICATIONS[J]. 2020, 第 6 作者 通讯作者 11(1): [14] Yang Changyong, Wang Lei, Sun Xing, Tang Mi, Quan Haitian, Zhang Lianshan, Lou Liguang, Gou Shaohua. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. ACTA PHARMACOLOGICA SINICA[J]. 2019, 第 7 作者40(7): 971-979, http://sciencechina.cn/gw.jsp?action=detail.jsp&internal_id=6532765&detailType=1.[15] Changyong Yang, Lei Wang, Xing Sun, Mi Tang, Haitian Quan, Lianshan Zhang, Liguang Lou, Shaohua Gou. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. 中国药理学报:英文版[J]. 2019, 第 7 作者40(7): 971-979, https://www.webofscience.com/wos/woscc/full-record/WOS:000472610000011.[16] Liu, CuiPing, Xie, ChengYing, Zhao, JinXin, Ji, KaiLong, Lei, XinXiang, Sun, Han, Lou, LiGuang, Yue, JianMin. Dysoxylactam A: A Macrocyclolipopeptide Reverses P-Glycoprotein-Mediated Multidrug Resistance in Cancer Cells. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY[J]. 2019, 第 7 作者 通讯作者 141(17): 6812-6816, [17] Zheng, Chao, Li, MingZong, You, TianPa, Tang, WeiPing, Lou, LiGuang. Synthesis and antitumor activity of a series of lactone-opened camptothecin derivatives. JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH[J]. 2019, 第 5 作者21(1): 51-61, [18] 王罗春, 瞿爱东, 楼丽广. 重组抗VEGF人源化单克隆抗体F0001的临床前主要药效学研究. 上海医药[J]. 2019, 第 3 作者40(13): 55-60, http://lib.cqvip.com/Qikan/Article/Detail?id=7002368931.[19] Liu, Peng, Chen, Xiangling, Zhu, Jianming, Li, Bo, Chen, Zhaoqiang, Wang, Guimin, Sun, Haiguo, Xu, Zhijian, Zhao, Zhixin, Zhou, Chen, Xie, Chengying, Lou, Liguang, Zhu, Weiliang. Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response. CHEMISTRYOPEN[J]. 2019, 第 12 作者 通讯作者 8(3): 344-353, [20] Wang, Lei, Yang, Changyong, Xie, Chengying, Jiang, Jiahua, Gao, Mingzhao, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Lou, Liguang. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. CANCER SCIENCE[J]. 2019, 第 10 作者 通讯作者 110(3): 1064-1075, https://www.webofscience.com/wos/woscc/full-record/WOS:000460316200021.[21] Tong, Mengya, Gao, Mingzhao, Xu, Yongping, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Lou, Liguang. SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met. CANCER SCIENCE[J]. 2019, 第 9 作者 通讯作者 110(11): 3584-3594, http://dx.doi.org/10.1111/cas.14180.[22] Long, Fei, He, Ye, Fu, Haoyu, Li, Yun, Bao, Xubin, Wang, Quanren, Wang, Yigang, Xie, Chengying, Lou, Liguang. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models. CANCER SCIENCE[J]. 2019, 第 9 作者 通讯作者 110(4): 1420-1430, [23] Gao Mingzhao, Wang Hongbin, Chen Xiangling, Cao Wenting, Fu Li, Li Yun, Quan Haitian, Xie Chengying, Lou Liguang. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. ACTA PHARMACOLOGICA SINICA[J]. 2019, 第 9 作者 通讯作者 40(2): 268-278, http://sciencechina.cn/gw.jsp?action=detail.jsp&internal_id=6464684&detailType=1.[24] Gao, Mingzhao, Zhu, Hongmei, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Quan, Haitian, Wang, Lei, Lou, Liguang. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants. CANCER SCIENCE[J]. 2019, 第 9 作者 通讯作者 110(10): 3306-3314, [25] Mingzhao Gao, Hongbin Wang, Xiangling Chen, Wenting Cao, Li Fu, Yun Li, Haitian Quan, Chengying Xie, Liguang Lou. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. ACTA PHARMACOLOGICA SINICA. 2018, 第 9 作者40(2): 268-278, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329746/.[26] Gao AnLi, Xiong QingFeng, Jiang Jing, Yu Juan, Lou LiGuang, Liu WeiPing. Design, Syntheses and Anticancer Activities of Platinum(IV) Prodrugs with Dihydrogen Phosphate as an Axial Ligand. CHINESE JOURNAL OF INORGANIC CHEMISTRY[J]. 2018, 第 5 作者34(9): 1649-1654, https://www.webofscience.com/wos/woscc/full-record/WOS:000446645600008.[27] Xie, Chengying, Zhao, Huajun, Bao, Xubin, Fu, Haoyu, Lou, Liguang. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE[J]. 2018, 第 5 作者 通讯作者 22(11): 5367-5377, https://www.webofscience.com/wos/woscc/full-record/WOS:000448279600018.[28] He, Ye, Sun, Liping, Xu, Yongping, Fu, Li, Li, Yun, Bao, Xubin, Fu, Haoyu, Xie, Chengying, Lou, Liguang. Combined inhibition of PI3K delta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia. CANCER LETTERS[J]. 2018, 第 9 作者 通讯作者 420: 49-59, https://www.webofscience.com/wos/woscc/full-record/WOS:000428098200005.[29] 高安丽, 熊庆丰, 姜婧, 余娟, 楼丽广, 刘伟平. 以磷酸二氢根为轴向配体的铂（Ⅳ）前药的设计、合成和抗癌活性测试. 无机化学学报[J]. 2018, 第 5 作者34(9): 1649-1654, http://lib.cqvip.com/Qikan/Article/Detail?id=7000792931.[30] Xie, Chengying, Wan, Xiaozhe, Quan, Haitian, Zheng, Mingyue, Fu, Li, Li, Yun, Lou, Liguang. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. CANCER SCIENCE[J]. 2018, 第 7 作者 通讯作者 109(4): 1207-1219, https://www.webofscience.com/wos/woscc/full-record/WOS:000429411800032.[31] Wang, Lei, Gao, Mingzhao, Tong, Mengya, Xie, Chengying, He, Ye, Fu, Li, Li, Yun, Fu, Haoyu, Lou, Liguang. Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. AMERICAN JOURNAL OF CANCER RESEARCH[J]. 2018, 第 9 作者 通讯作者 8(8): 1541-1550, https://www.webofscience.com/wos/woscc/full-record/WOS:000443206500015.[32] Wang, Lei, Wang, Quanren, Gao, Mingzhao, Fu, Li, Li, Yun, Quan, Haitian, Lou, Liguang. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. CANCER SCIENCE[J]. 2018, 第 7 作者 通讯作者 109(10): 3305-3315, https://www.webofscience.com/wos/woscc/full-record/WOS:000446319600030.[33] Jiang, Jing, Qiu, Jie, Lou, Liguang, Gao, Anli, Hou, Shuqian, Liu, Weiping. Non-coordination planer cis-and trans-configuration of cis-Pt(II)(mixed-NH3/RNH2)(3-OH-cyclobutane-1,1-dicarboxylate): separation, characterization, and anticancer activity. RESEARCH ON CHEMICAL INTERMEDIATES[J]. 2018, 第 3 作者44(11): 6479-6487, https://www.webofscience.com/wos/woscc/full-record/WOS:000449307900003.[34] 冯洋洋, 杨知微, 常桥稳, 刘伟平, 楼丽广, 姜婧. 1，5-环辛二烯氯化铱的HPLC法测定. 贵金属[J]. 2018, 第 5 作者39(A01): 219-222, http://lib.cqvip.com/Qikan/Article/Detail?id=7000934910.[35] Chen, Xiangling, Liu, Peng, Wang, Quanren, Li, Yun, Fu, Li, Fu, Haoyu, Zhu, Jianming, Chen, Zhaoqiang, Zhu, Weiliang, Xie, Chengying, Lou, Liguang. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp9O-Cdc37 interaction. CANCER LETTERS[J]. 2018, 第 11 作者 通讯作者 434: 70-80, https://www.webofscience.com/wos/woscc/full-record/WOS:000444666500007.[36] Ye He, Liping Sun, Yongping Xu, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Chengying Xie, Liguang Lou. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia. CANCER LETTERS. 2018, 第 9 作者420: 49-59, http://dx.doi.org/10.1016/j.canlet.2018.01.071.[37] Zhong, Chenchun, Chen, Feng, Yang, Junling, Jia, Weiwei, Li, Li, Cheng, Chen, Du, Feifei, Zhang, Suping, Xie, Chengying, Zhang, Nating, Olaleye, Olajide E, Wang, Fengqing, Xu, Fang, Lou, Liguang, Chen, Dongying, Niu, Wei, Li, Chuan. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species. ACTA PHARMACOLOGICA SINICA[J]. 2018, 第 14 作者39(6): 1048-1063, http://lib.cqvip.com/Qikan/Article/Detail?id=675611227.[38] Li, Xin, Yang, Changyong, Wan, Hong, Zhang, Ge, Feng, Jun, Zhang, Lei, Chen, Xiaoyan, Zhong, Dafang, Lou, Liguang, Tao, Weikang, Zhang, Lianshan. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES[J]. 2017, 第 9 作者110: 51-61, http://dx.doi.org/10.1016/j.ejps.2017.01.021.[39] Xie, Chengying, Chen, Xiangling, Zheng, Mingyue, Liu, Xiaohong, Wang, Hongbin, Lou, Liguang. Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin. ONCOTARGET[J]. 2017, 第 6 作者 通讯作者 8(64): 107977-107990, http://dx.doi.org/10.18632/oncotarget.22439.[40] 楼丽广. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in HER2-positive gastric cancer cells. Cancer Sciences. 2017, 第 1 作者 通讯作者 [41] Xie, Chengying, He, Ye, Zhen, Mingyue, Wang, Yulan, Xu, Yongping, Lou, Liguang. Puquitinib, a novel orally available PI3K inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. CANCER SCIENCE[J]. 2017, 第 6 作者 通讯作者 108(7): 1476-1484, https://www.webofscience.com/wos/woscc/full-record/WOS:000404963700023.[42] Gao AnLi, Qiu Jie, Hou ShuQian, Jiang Jing, Lou LiGuang, Liu WeiPing. Synthesis and Anticancer Activity of cis-Pt(II)(trans-1,2-bis(methylamino)cyclobutane) (3-hydroxyl-1,1-cyclobutanedicarboxylate). CHINESE JOURNAL OF INORGANIC CHEMISTRY[J]. 2017, 第 5 作者33(5): 837-842, https://www.webofscience.com/wos/woscc/full-record/WOS:000405542200015.[43] Wang, Hongbin, Wang, Wenqian, Xu, Yongping, Yang, Yong, Chen, Xiaoyan, Quan, Haitian, Lou, Liguang. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. CANCER SCIENCE[J]. 2017, 第 7 作者 通讯作者 108(7): 1458-1468, https://www.webofscience.com/wos/woscc/full-record/WOS:000404963700021.[44] Wang, Hongbin, Quan, Haitian, Lou, Liguang. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS[J]. 2017, 第 3 作者 通讯作者 489(1): 14-20, http://dx.doi.org/10.1016/j.bbrc.2017.05.110.[45] 高安丽, 邱洁, 侯树谦, 姜婧, 楼丽广, 刘伟平. cis-（trans-1，2-双（氨甲基）环丁烷）（3-羟基-1，1-环丁烷二羧酸根）合铂（Ⅱ）的合成和抗癌活性. 无机化学学报[J]. 2017, 第 5 作者33(5): 837-842, http://lib.cqvip.com/Qikan/Article/Detail?id=671999603.[46] Lu, YaNan, Cui, Ping, Tian, XiaoQing, Lou, LiGuang, Fan, ChengQi. Unusual Cytotoxic Steroidal Saponins from the Gorgonian Astrogorgia dumbea. PLANTA MEDICA[J]. 2016, 第 4 作者82(9-10): 882-887, https://www.webofscience.com/wos/woscc/full-record/WOS:000378913600014.[47] Wang, Wenqian, Liu, Yang, Zhao, Zhixin, Xie, Chengying, Xu, Yongping, Hu, Youhong, Quan, Haitian, Lou, Liguang. Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo. CANCER SCIENCE[J]. 2016, 第 8 作者107(6): 782-790, https://www.webofscience.com/wos/woscc/full-record/WOS:000378715100009.[48] Zhao, Zhixin, Zhu, Jianming, Quan, Haitian, Wang, Guimin, Li, Bo, Zhu, Weiliang, Xie, Chengying, Lou, Liguang. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response. ONCOTARGET[J]. 2016, 第 8 作者 通讯作者 7(20): 29648-29663, https://www.webofscience.com/wos/woscc/full-record/WOS:000377742600070.[49] Li, Hongwen, Yu, Chao, Jiang, Jing, Huang, Changjiang, Yao, Xuejing, Xu, Qiaoyu, Yu, Fang, Lou, Liguang, Fang, Jianmin. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. CANCER BIOLOGY & THERAPY[J]. 2016, 第 8 作者17(4): 346-354, https://dx.doi.org/10.1080/15384047.2016.1139248.[50] 高明钊, 楼丽广. 异柠檬酸脱氢酶（IDH1与IDH2）突变促进肿瘤生成的机制探索. 2015, 第 2 作者186, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=IPFD&dbname=IPFDLAST2016&filename=ZGKA201504001128&v=MDM3MjRxNDlGWmVvTkJCTkt1aGRobmo5OFRuanFxeGRFZU1PVUtyaWZaZVp2SGludFU3L0xJRjhTUHlyQWI3RzRIOVRN.[51] 王文倩, 全海天, 楼丽广. 新型Hsp90抑制剂Y-632的抗肿瘤作用及机制研究. 2015, 第 3 作者248, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=IPFD&dbname=IPFDLAST2016&filename=ZGKA201504001182&v=MDcwNzJUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVNy9MSUZ3ZFB5ckFiN0c0SDlUTXE0OUZaZW9IRGhOS3VoZGhuajk4.[52] Yao, Xuejing, Jiang, Jing, Wang, Xin, Huang, Changjiang, Li, Dong, Xie, Kuan, Xu, Qiaoyu, Li, Hongwen, Li, Zhuanglin, Lou, Liguang, Fang, Jianmin. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. BREAST CANCER RESEARCH AND TREATMENT[J]. 2015, 第 10 作者153(1): 123-133, https://www.webofscience.com/wos/woscc/full-record/WOS:000359775100012.[53] 王洪斌, 全海天, 楼丽广. Sonic hedgehog信号通路在肺癌对表皮生长因子受体抑制剂获得性抗药中的地位. 2015, 第 3 作者245, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=IPFD&dbname=IPFDLAST2016&filename=ZGKA201504001179&v=MDQ1MDhuajk4VG5qcXF4ZEVlTU9VS3JpZlplWnZIaW50VTcvTElGMFZQeXJBYjdHNEg5VE1xNDlGWmVvSUJSTkt1aGRo.[54] Jiang, Jing, Lei, Jing, Chen, XiZhu, Lou, LiGuang, Ye, QingSong, Chang, QiaoWen, Xu, YongPing, Liu, WeiPing. Synthesis and anticancer activity of a new water-soluble derivative of heptaplatin, cis-{Pt(II)(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane(3-acetoxyl-cyclobutane-1,1-dicarboxylato)}. RESEARCH ON CHEMICAL INTERMEDIATES[J]. 2015, 第 4 作者41(9): 6149-6155, https://www.webofscience.com/wos/woscc/full-record/WOS:000361140200017.[55] Wu, Lixian, Yu, Jing, Chen, Ruijia, Liu, Yang, Lou, Liguang, Wu, Ying, Huang, Lisen, Fan, Yingjuan, Gao, Pinzhang, Huang, Meijuan, Wu, Yong, Chen, Yuanzhong, Xu, Jianhua. Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells. CLINICAL CANCER RESEARCH[J]. 2015, 第 5 作者21(4): 833-843, https://www.webofscience.com/wos/woscc/full-record/WOS:000349851200021.[56] Wang, Sinan, Yu, Yang, Chen, Xuyun, Zhu, Haipan, Du, Peile, Liu, Guohua, Lou, Liguang, Li, Hao, Wang, Wei. FeCl3-catalyzed selective acylation of amines with 1,3-diketones via C-C bond cleavage. TETRAHEDRON LETTERS[J]. 2015, 第 7 作者56(23): 3093-3096, http://dx.doi.org/10.1016/j.tetlet.2014.12.146.[57] 卫江明, 盛晔, 孙旭, 楼丽广, 隋东虎. 洛铂对体外培养人卵巢癌细胞增殖的抑制作用. 中国新药与临床杂志[J]. 2015, 第 4 作者34(4): 270, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFDLAST2015&filename=XYYL201504007&v=MjExMDZxZmIrWm1GeWpsVkx2T1BUVFNZckc0SDlUTXE0OUZZNFI4ZVgxTHV4WVM3RGgxVDNxVHJXTTFGckNVUjc=.[58] Liu, Weiping, Jiang, Jing, Xu, Yongping, Hou, Shuqian, Sun, Liping, Ye, Qingsong, Lou, Liguang. Design, synthesis and anticancer activity of diam(m)ine platinum(II) complexes bearing a small-molecular cell apoptosis inducer dichloroacetate. JOURNAL OF INORGANIC BIOCHEMISTRY[J]. 2015, 第 7 作者 通讯作者 146: 14-18, http://dx.doi.org/10.1016/j.jinorgbio.2015.02.002.[59] Zhao, Jie, Quan, Haitian, Xie, Chengying, Lou, Liguang. NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. PHARMACOLOGY RESEARCH & PERSPECTIVES[J]. 2014, 第 4 作者 通讯作者 2(3): [60] Sun, Xu, Lou, LiGuang, Sui, DongHu, Wu, XiaoHua. Preclinical Activity of Lobaplatin as a Single Agent and in Combination with Taxanes for Ovarian Carcinoma Cells. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION[J]. 2014, 第 2 作者 通讯作者 15(22): 9939-9943, https://www.webofscience.com/wos/woscc/full-record/WOS:000351056900066.[61] Jiang Jing, Lou LiGuang, Chen XiZhu, Xu YongPing, Ye QingSong, Liu WeiPing. Synthesis and Anti-Tumor Activity of Two New Water-Soluble Derivatives of Heptaplatin. CHINESE JOURNAL OF INORGANIC CHEMISTRY[J]. 2014, 第 2 作者30(2): 317-322, https://www.webofscience.com/wos/woscc/full-record/WOS:000332434100013.[62] Liu, Weiping, Jiang, Jing, Xie, Chengying, Hou, Shuqian, Quan, Haitian, Ye, Qingsong, Lou, Liguang. Synthesis, anticancer activity and toxicity of a water-soluble 4S,5S-derivative of heptaplatin, cis-{Pt(II)(4S,5S)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane.(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}. JOURNAL OF INORGANIC BIOCHEMISTRY[J]. 2014, 第 7 作者 通讯作者 140: 126-130, http://dx.doi.org/10.1016/j.jinorgbio.2014.07.013.[63] 楼丽广. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes imatinib- and sunitinib- resistance of certain KIT mutants. Cancer Science. 2014, 第 1 作者 通讯作者 [64] Jiang Jing, Lou LiGuang, Chen XiZhu, Xu YongPing, Ye QingSong, Liu WeiPing. Synthesis and Anti-Tumor Activity of Two New Water-Soluble Derivatives of Heptaplatin. CHINESE JOURNAL OF INORGANIC CHEMISTRY[J]. 2014, 第 2 作者30(2): 317-322, https://www.webofscience.com/wos/woscc/full-record/WOS:000332434100013.[65] Zhao, Jie, Quan, Haitian, Xu, Yongping, Kong, Xiangqian, Jin, Lu, Lou, Liguang. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. CANCER SCIENCE[J]. 2014, 第 6 作者 通讯作者 105(1): 117-125, https://www.webofscience.com/wos/woscc/full-record/WOS:000331129900015.[66] Wu, Lixian, Wu, Ying, Chen, Ruijia, Liu, Yang, Huang, Lisen, Lou, Liguang, Zheng, Zhihong, Chen, Yuanzhong, Xu, Jianhua. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. ACTA PHARMACOLOGICA SINICA[J]. 2014, 第 6 作者35(3): 401-409, https://www.webofscience.com/wos/woscc/full-record/WOS:000332467200011.[67] Sun, Liping, Quan, Haitian, Xie, Chengying, Wang, Lei, Hu, Youhong, Lou, Liguang. Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition. PLOS ONE[J]. 2014, 第 6 作者 通讯作者 9(3): https://doaj.org/article/e9a8f2d0c1ae43a28fb6f034eb0696c7.[68] 赵之欣, 谢成英, 楼丽广. 新型Hsp90抑制剂X66抗肿瘤作用机制研究. 2013, 第 3 作者36-37, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS201305001015&v=MjkxMjZHNEg5TE1xbzlGWmVzT0NSTkt1aGRobmo5OFRuanFxeGRFZU1PVUtyaWZaZVp2SGludFU3ektKMW9VUHlyU2Zi.[69] 楼丽广. Cis-[Pt(II)(1R,2R-DACH)(3-Acetoxy- 1,1- cyclobutanedicarboxylato)]:a water-soluble,oxalate-free and stable analogue of oxaliplatin: synthesis, characterization and biological Valuations. ChemMedChem. 2013, 第 1 作者 通讯作者 [70] Liu, Weiping, Ye, Qingsong, Jiang, Jing, Lou, Liguang, Xu, Yongping, Xie, Chengying, Xie, Mingjin. cis-Pt-II(1R,2R-DACH)(3-acetoxy-1,1-cyclobutanedicarboxylato). CHEMMEDCHEM[J]. 2013, 第 4 作者 通讯作者 8(9): 1465-1467, https://www.webofscience.com/wos/woscc/full-record/WOS:000323541300010.[71] Wang, Quanren, Quan, Haitian, Zhao, Jie, Xie, Chengying, Wang, Lei, Lou, Liguang. RON confers lapatinib resistance in HER2-positive breast cancer cells. CANCER LETTERS[J]. 2013, 第 6 作者 通讯作者 340(1): 43-50, http://dx.doi.org/10.1016/j.canlet.2013.06.022.[72] 王蕾, 楼丽广. 全新雷公藤内酯醇衍生物LLDT-144的抗肿瘤作用和与Hsp90抑制剂的协同作用研究. 2013, 第 2 作者72-73, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS201305001050&v=MzIyODRuajk4VG5qcXF4ZEVlTU9VS3JpZlplWnZIaW50VTd6S0oxMFJQeXJTZmJHNEg5TE1xbzlGWmVzS0RCTkt1aGRo.[73] Xing, Yingjuan, Lou, Liguang, Chen, Xizhu, Ye, Qingsong, Xu, Yongping, Xie, Chengying, Jiang, Jing, Liu, Weiping. Synthesis and cytotoxicity of diam(m)ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the leaving group. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS[J]. 2012, 第 2 作者22(6): 2239-2241, http://dx.doi.org/10.1016/j.bmcl.2012.01.091.[74] Xie, ChengYing, Xu, YongPing, Zhao, HongBing, Lou, LiGuang. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists. EXPERIMENTAL HEMATOLOGY[J]. 2012, 第 4 作者 通讯作者 40(5): 386-392, http://dx.doi.org/10.1016/j.exphem.2012.01.010.[75] Wang, Lei, Xu, Yongping, Fu, Li, Li, Yuanchao, Lou, Liguang. (5R)-5-hydroxytriptolide (LLDT-8), a novel immunosuppressant in clinical trials, exhibits potent antitumor activity via transcription inhibition. CANCER LETTERS[J]. 2012, 第 5 作者 通讯作者 324(1): 75-82, http://dx.doi.org/10.1016/j.canlet.2012.05.004.[76] Liu, Weiping, Chen, Xizhu, Ye, Qingsong, Hou, Shuqian, Lou, Liguang, Xie, Chengying. 3-Hydroxycarboplatin, a Simple Carboplatin Derivative Endowed with an Improved Toxicological Profile. PLATINUM METALS REVIEW[J]. 2012, 第 5 作者56(4): 248-256, https://www.webofscience.com/wos/woscc/full-record/WOS:000313558800006.[77] Xie, ChengYing, Xu, YongPing, Jin, Wei, Lou, LiGuang. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. ANTI-CANCER DRUGS[J]. 2012, 第 4 作者 通讯作者 23(7): 698-705, https://www.webofscience.com/wos/woscc/full-record/WOS:000305894700004.[78] Wu, Qiong, Quan, Haitian, Xu, Yongping, Li, Yun, Hu, Youhong, Lou, Liguang. p38 Mitogen-Activated Protein Kinase Is Required for the Antitumor Activity of the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-acetic Acid. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS[J]. 2012, 第 6 作者 通讯作者 341(3): 709-717, https://www.webofscience.com/wos/woscc/full-record/WOS:000304445000016.[79] Lou, Liguang, Wu, Qiong, Quan, Haitian, Xu, Yongping. p38 MAPK is required for the antitumor activity of the vascular disrupting agent DMXAA. CANCER RESEARCH. 2012, 第 1 作者72: https://www.webofscience.com/wos/woscc/full-record/WOS:000209701500280.[80] Zhao, Hongbing, Quan, Haitian, Xie, Chengying, Xu, Yongping, Xie, Fuchun, Hu, Youhong, Lou, Liguang. YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance. CANCER LETTERS[J]. 2012, 第 7 作者 通讯作者 314(1): 54-62, http://dx.doi.org/10.1016/j.canlet.2011.09.013.[81] Liu, Weiping, Chen, Xizhu, Ye, Qingsong, Xu, Yongping, Xie, Chengying, Xie, Mingjin, Chang, Qiaowen, Lou, Liguang. A Novel Water-Soluble Heptaplatin Analogue with Improved Antitumor Activity and Reduced Toxicity. INORGANIC CHEMISTRY[J]. 2011, 第 8 作者 通讯作者 50(12): 5324-5326, https://www.webofscience.com/wos/woscc/full-record/WOS:000291422100006.[82] 黄勇, 秦叔逵, 隋东虎, 李进, 楼丽广. 不同铂类为主联合化疗抗人肺癌细胞株的药效学研究. 临床肿瘤学杂志[J]. 2011, 第 5 作者16(3): 201-205, http://lib.cqvip.com/Qikan/Article/Detail?id=37700267.[83] Xie, Chengying, Xu, Yongping, Lou, Liguang. Preclinical study of puquitinib, a novel orally available PI3K inhibitor in phase I clinical trials. CANCER RESEARCH. 2011, 第 3 作者71: https://www.webofscience.com/wos/woscc/full-record/WOS:000209701303461.[84] 秦叔逵, 黄勇, 隋东虎, 李进, 楼丽广. 不同铂类联合紫杉类或长春瑞滨对非小细胞肺癌荷瘤裸鼠抑瘤作用的实验研究. 临床肿瘤学杂志[J]. 2011, 第 5 作者16(3): 206-210, http://lib.cqvip.com/Qikan/Article/Detail?id=37700269.[85] Zhang, HaiBo, Pu, JianXin, Zhao, Yong, He, Fei, Li, XiaoNian, Luo, Xiao, Lou, LiGuang, Sun, HanDong. Bisleuconins A-D: a pair of epimeric ent-kauranoid dimers and two new asymmetric analogues isolated from Isodon leucophyllus. TETRAHEDRON LETTERS[J]. 2011, 第 7 作者52(46): 6061-6066, http://dx.doi.org/10.1016/j.tetlet.2011.08.133.[86] Xie, Fuchun, Zhao, Hongbing, Li, Dewen, Chen, Hong, Quan, Haitian, Shi, Xiaojing, Lou, Liguang, Hu, Youhong. Synthesis and Biological Evaluation of 2,4,5-Substituted Pyrimidines as a New Class of Tubulin Polymerization Inhibitors. JOURNAL OF MEDICINAL CHEMISTRY[J]. 2011, 第 7 作者 通讯作者 54(9): 3200-3205, https://www.webofscience.com/wos/woscc/full-record/WOS:000290126800006.[87] 全海天, 田姝, 谢成英, 郭海宜, 吕芳芳, 徐永平, 李进, 楼丽广. 新型VEGFR2/KDR选择性抑制剂YN968D1的体内外抗肿瘤作用及机制研究. 2011, 第 8 作者53, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGKA201104002048&v=Mjc3NTJlTU9VS3JpZlplWnZIaW50VTd2S0kxc1RQeXJBYjdHNEg5RE1xNDlGWnVzTEJCTkt1aGRobmo5OFRuanFxeGRF.[88] Lou, Liguang, Mi, Yi, Xu, Yongping, Xie, Chengying, Zhao, Hongbing. Preclinical antitumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR/PDGFR/c-Kit in phase I clinical trials. CANCER RESEARCH. 2011, 第 1 作者71: https://www.webofscience.com/wos/woscc/full-record/WOS:000209701401170.[89] 王蕾, 楼丽广. 雷公藤衍生物LLDT-8的体内外抗肿瘤活性及机制研究. 2011, 第 2 作者54, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGKA201104002050&v=MDY5MDJudFU3dktJMTRXUHlyQWI3RzRIOURNcTQ5Rlp1c0tEQk5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhp.[90] Quan, Haitian, Xie Chengying, Xu, Yongping, Lou Liguang. Preclinical anti-tumor study of henatinib, a novel and selective inhibitor of VEGFR-2 in phase I clinical trials. CANCER RESEARCH. 2011, 第 4 作者71: https://www.webofscience.com/wos/woscc/full-record/WOS:000209701303474.[91] 吴琼, 楼丽广. P38 MAPK在DMXAA的抗肿瘤活性中起重要作用. 2011, 第 2 作者52, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGKA201104002047&v=MDM5MTVNcTQ5Rlp1c0xDeE5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVN3ZLSWxzWFB5ckFiN0c0SDlE.[92] Tian, Shu, Quan, Haitian, Xie, Chengying, Guo, Haiyi, Lue, Fangfang, Xu, Yongping, Li, Jin, Lou, Liguang. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. CANCER SCIENCE[J]. 2011, 第 8 作者102(7): 1374-1380, https://www.webofscience.com/wos/woscc/full-record/WOS:000292863100019.[93] Yin, Runting, Gou, Shaohua, Liu, Xia, Lou, Liguang. Antitumor activities and interaction with DNA of oxaliplatin-type platinum complexes with linear or branched alkoxyacetates as leaving groups. JOURNAL OF INORGANIC BIOCHEMISTRY[J]. 2011, 第 4 作者105(8): 1095-1101, http://dx.doi.org/10.1016/j.jinorgbio.2011.05.005.[94] 朱雪莲, 杨卓, 徐志建, 楼丽广, 朱维良. 靶向HSP90及HSP70的双效抑制剂. 2010, 第 4 作者78, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGHY201006016074&v=MDY3NjVyaWZaZVp2SGludFU3cktJVjhWUHlyRGQ3RzRIOUhNcVk5RVl1c0lDQk5LdWhkaG5qOThUbmpxcXhkRWVNT1VL.[95] Xie, Mingjin, Liu, Weiping, Lou, Liguang, Chen, Xizhu, Ye, Qingsong, Yu, Yao, Chang, Qiaowen, Hou, Shuqian. Unusual Dimeric Chemical Structure for a Carboplatin Analogue as a Potential Anticancer Complex. INORGANIC CHEMISTRY[J]. 2010, 第 3 作者49(13): 5792-5794, http://ir.simm.ac.cn/handle/153631/2013.[96] Zhang, Hai Bo, Pu, Jian Xin, Zhao, Yong, He, Fei, Zhao, Wei, Lou, Li Guang, Xiao, Wei Lie, Sun, Han Dong. Three New 18-Oxygenated ent-Kaurane Diterpenoids from Isodon leucophyllus. NATURAL PRODUCT COMMUNICATIONS[J]. 2010, 第 6 作者5(12): 1873-1876, https://www.webofscience.com/wos/woscc/full-record/WOS:000285487000006.[97] Luo, H, Quan, H, Xie, C, Xu, Y, Fu, L, Lou, L. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. LEUKEMIA. 2010, 24(10): 1807-1809, http://www.corc.org.cn/handle/1471x/2375748.[98] Li, XiaoNian, Pu, JianXin, Du, Xue, Lou, LiGuang, Li, LiMei, Huang, ShengXiong, Zhao, Bo, Zhang, Mei, He, Fei, Luo, Xiao, Xiao, WeiLie, Sun, HanDong. Structure and Cytotoxicity of Diterpenoids from Isodon eriocalyx. JOURNAL OF NATURAL PRODUCTS[J]. 2010, 第 4 作者73(11): 1803-1809, http://ir.simm.ac.cn/handle/153631/1949.[99] 谢成英, 金炜, 徐永平, 楼丽广. 洛铂对非小细胞肺癌作用的临床前药效学研究. 2009, 第 4 作者206, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS200904001182&v=MjQ1MTFXUHlyU2ZiRzRIdGpNcTQ5Rlplb0hEaE5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVN3ZOSWww.[100] Lu, HongFu, Sun, Xun, Xu, Liang, Lou, LiGuang, Lin, GuoQiang. Design, synthesis and biological evaluation of novel fluorinated docetaxel analogues. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY[J]. 2009, 第 4 作者44(2): 482-491, http://dx.doi.org/10.1016/j.ejmech.2008.04.004.[101] Li, Mingzong, Jin, Wei, Jiang, Chen, Zheng, Chao, Tang, Weidong, You, Tianpa, Lou, Liguang. 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS[J]. 2009, 第 7 作者19(15): 4107-4109, http://dx.doi.org/10.1016/j.bmcl.2009.06.010.[102] Xie, Fuchun, Zhao, Hongbing, Zhao, Lizhi, Lou, Liguang, Hu, Youhong. Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS[J]. 2009, 第 4 作者 通讯作者 19(1): 275-278, http://dx.doi.org/10.1016/j.bmcl.2008.09.067.[103] Quan, Haitian, Liu, Houfu, Li, Chuan, Lou, Liguang. 1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) Enhances the Cytotoxicity of Combretastatin A4 Independently of Mitogen-Activated Protein Kinase Kinase. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS[J]. 2009, 第 4 作者 通讯作者 330(1): 326-333, http://ir.simm.ac.cn/handle/153631/1153.[104] 楼丽广. Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity. Bioorg.. Med. Chem. Lett.. 2009, 第 1 作者 通讯作者 [105] 罗海山, 楼丽广. HH-GV-678抗慢性粒细胞白血病活性的临床前药效学研究. 2009, 第 2 作者171, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS200904001142&v=MTIwNjVuanFxeGRFZU1PVUtyaWZaZVp2SGludFU3dk5JbDhjUHlyU2ZiRzRIdGpNcTQ5Rlplb0xEaE5LdWhkaG5qOThU.[106] 赵红兵, 楼丽广. 新型2，4，5-取代嘧啶类化合物的抗肿瘤机制研究. 2009, 第 2 作者226-227, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS200904001206&v=MjQ4ODZudFU3dk5KRjhWUHlyU2ZiRzRIdGpNcTQ5Rlpla1BDaE5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhp.[107] 全海天, 楼丽广. U0126增强combretastatin A4细胞毒性的作用不依赖于MEK. 2009, 第 2 作者178-179, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD0914&filename=ZGYS200904001151&v=MDY1OTdiRzRIdGpNcTQ5Rlplb0tEUk5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVN3ZOS0ZzVVB5clNm.[108] Chen, Chuan, Qiang, Shigao, Lou, Liguang, Zhao, Weimin. Cucurbitane-Type Triterpenoids from the Stems of Cucumis melo. JOURNAL OF NATURAL PRODUCTS[J]. 2009, 第 3 作者 通讯作者 72(5): 824-829, http://ir.simm.ac.cn/handle/153631/1205.[109] Shao, Yong, Zhang, HanKun, Ding, Hong, Quan, HaiTian, Lou, LiGuang, Hu, LiHong. Synthesis and Structure-Activity Relationship Studies of Cytotoxic Anhydrovinblastine Amide Derivatives. JOURNAL OF NATURAL PRODUCTS[J]. 2009, 第 5 作者72(6): 1170-1177, http://ir.simm.ac.cn/handle/153631/1178.[110] Liu, WeiPing, Ye, QingSong, Yu, Yao, Chen, XiZhu, Hou, ShuQian, Lou, LiGuang, Yang, YongPing, Wang, YiMing, Su, Qiang. Novel Lipophilic Platinum(II) Compounds of Salicylate Derivatives RESEARCH, DEVELOPMENT AND LIPOSOMAL FORMULATION. PLATINUM METALS REVIEW[J]. 2008, 第 6 作者52(3): 163-171, http://ir.simm.ac.cn/handle/153631/1371.[111] Chen, XiZhu, Ye, OingSong, Lou, LiGuang, Xie, MingJin, Liu, WeiPing, Yu, Yao, Hou, ShuQian. Synthesis and cytotoxicity of platinum(III) complexes of a physiologically active carrier histamine. ARCHIV DER PHARMAZIE[J]. 2008, 第 3 作者341(2): 132-136, http://ir.simm.ac.cn/handle/153631/439.[112] Gao, XueMei, Pu, JianXin, Huang, ShengXiong, Lu, Yang, Lou, LiGuang, Li, RongTao, Xiao, WeiLie, Chang, Ying, Sun, HanDong. Kadcoccilactones A-J, triterpenoids from Kadsura coccinea. JOURNAL OF NATURAL PRODUCTS[J]. 2008, 第 5 作者71(7): 1182-1188, http://www.corc.org.cn/handle/1471x/2387827.[113] 黄孝春, 刘海利, 楼丽广, 郭跃伟. 两种南海倔海绵Dysidea villosa和Dysidea marshalla的化学成分. 中国天然药物[J]. 2008, 第 3 作者6(6): 425-429, http://lib.cqvip.com/Qikan/Article/Detail?id=28917702.[114] 徐永平, 唐卫东, 王蕾, 李援朝, 楼丽广. 新型雷公藤内酯醇化合物抗肿瘤作用研究. 2008, 第 5 作者80, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD9908&filename=ZGZP200809004014&v=MTYyODVqOThUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVN2pNSVZzZFB5clJmckc0SHRuTXBvOUZZT3NPQ0JOS3VoZGhu.[115] Ma, ChunHui, Fan, MingSong, Lin, LiPing, Tang, WeiDong, Lou, LiGuang, Ding, Jian, Huang, ChengGang. Cytotoxic triterpenoid saponins from Vaccaria segetalis. JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH[J]. 2008, 第 5 作者10(2): 177-184, https://www.webofscience.com/wos/woscc/full-record/WOS:000256384400011.[116] Quan, Haitian, Xu, Yongping, Lou, Liguang. P38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4. INTERNATIONAL JOURNAL OF CANCER[J]. 2008, 第 3 作者 通讯作者 122(8): 1730-1737, https://www.webofscience.com/wos/woscc/full-record/WOS:000254068300009.[117] Yu, Yao, Lou, LiGuang, Liu, WeiPing, Zhu, HuaJie, Ye, QingSong, Chen, XiZhu, Gao, WenGui, Hou, ShuQian. Synthesis and anticancer activity of lipophilic platinum(II) complexes of 3,5-diisopropylsalicylate. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY[J]. 2008, 第 2 作者43(7): 1438-1443, http://dx.doi.org/10.1016/j.ejmech.2007.09.006.[118] 刘悦, 雷新胜, 宫爱申, 肖亮, 孙易, 全海天, 徐永平, 唐卫东, 楼丽广, 邓炳初. 全新长春氟宁衍生物体内外药效筛选. 中国新药杂志[J]. 2008, 第 9 作者17(19): 1659, http://lib.cqvip.com/Qikan/Article/Detail?id=28470781.[119] Li, Mingzong, Tang, Weidong, Zeng, Fuxing, Lou, Liguang, You, Tianpa. Semi-synthesis and biological activity of gamma-lactones analogs of camptothecin. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS[J]. 2008, 第 4 作者 通讯作者 18(24): 6441-6443, http://ir.simm.ac.cn/handle/153631/466.[120] 叶青松, 楼丽广, 刘伟平, 余尧, 侯树谦. 铂类抗肿瘤药物靶向给药的研究进展. 中国药学杂志[J]. 2008, 第 2 作者43(20): 1521, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFQ&dbname=CJFD2008&filename=ZGYX200820002&v=MTY2NTZyV00xRnJDVVI3cWZiK1ptRnkvblVMekJQeXJTZHJHNEh0bk9yNDlGWm9SOGVYMUx1eFlTN0RoMVQzcVQ=.[121] Gao, XueMei, Pu, JianXin, Xiao, WeiLie, Huang, ShengXiong, Lou, LiGuang, Sun, HanDong. Kadcoccilactones K-R, triterpenoids from Kadsura coccinea. TETRAHEDRON[J]. 2008, 第 5 作者64(51): 11673-11679, http://dx.doi.org/10.1016/j.tet.2008.10.011.[122] Meng, Dahai, Qiang, Shigao, Lou, Liguang, Zhao, Weimin. Cytotoxic Cucurbitane-Type Triterpenoids from Elaeocarpus hainanensis. PLANTA MEDICA[J]. 2008, 第 3 作者74(14): 1741-1744, http://ir.simm.ac.cn/handle/153631/1345.[123] Zhao, Yu, Guo, Na, Lou, LiGuang, Cong, YuWen, Peng, LiYan, Zhao, QinShi. Synthesis, cytotoxic activity, and SAR analysis of the derivatives of taxchinin A and brevifoliol. BIOORGANIC & MEDICINAL CHEMISTRY[J]. 2008, 第 3 作者16(9): 4860-4871, http://dx.doi.org/10.1016/j.bmc.2008.03.041.[124] Weiping Liu, Xizhu Chen, Mingjin Xie, Liguang Lou, Qingsong Ye, Yao Yu, Shuqian Hou. Synthesis and anticancer activity of 2-hydroxy-1,3-diaminopropane- κ2N, N′ platinum(II) complexes. JOURNALOFINORGANICBIOCHEMISTRY. 2008, 第 4 作者102(10): 1942-1946, http://dx.doi.org/10.1016/j.jinorgbio.2008.07.003.[125] Liu, Weiping, Chen, Xizhu, Xie, Mingjin, Lou, Liguang, Ye, Qingsong, Yu, Yao, Hou, Shuqian. Synthesis and anticancer activity of 2-hydroxy-1,3-diaminopropane-K-2 N,N ' platinum(II) complexes. JOURNAL OF INORGANIC BIOCHEMISTRY[J]. 2008, 第 4 作者102(10): 1942-1946, https://www.webofscience.com/wos/woscc/full-record/WOS:000259385700013.[126] Xie, Fuchun, Li, Shukun, Bai, Donglu, Lou, Liguang, Hu, Youhong. Three-component, one-pot synthesis of 2,4,5-substituted pyrimidines library for screening against human hepatocellular carcinoma BEL-7402 cells. JOURNAL OF COMBINATORIAL CHEMISTRY[J]. 2007, 第 4 作者9(1): 12-13, http://ir.simm.ac.cn/handle/153631/1905.[127] Ma, Lei, Ali, Mumtaz, Arfan, Mohammad, Lou, LiGuang, Hu, LiHong. Withaphysanolide A, a novel C-27 norwithanolide skeleton, and other cytotoxic compounds from Physalis divericata. TETRAHEDRON LETTERS[J]. 2007, 第 11 作者48(3): 449-452, http://dx.doi.org/10.1016/j.tetlet.2006.11.081.[128] Shao, Yong, Ding, Hong, Tang, Weidong, Lou, Liguang, Hu, Lihong. Synthesis and structure-activity relationships study of novel anti-tumor carbamate anhydrovinblastine analogues. BIOORGANIC & MEDICINAL CHEMISTRY[J]. 2007, 第 4 作者 通讯作者 15(15): 5061-5075, http://dx.doi.org/10.1016/j.bmc.2007.05.045.[129] 楼丽广. 中国抗肿瘤创新药物研究进展. 2007, 第 1 作者121, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD9908&filename=ZGKA200706001035&v=MTU3MThkRWVNT1VLcmlmWmVadkhpbnRVN25JSUZ3V1B5ckFiN0c0SHRiTXFZOUZaZXNNQ1JOS3VoZGhuajk4VG5qcXF4.[130] 肖亮, 全海天, 徐永平, 唐卫东, 富丽, 楼丽广. 长春氟宁抗肿瘤作用的研究. 中国药理学通报[J]. 2007, 第 6 作者23(4): 507, http://lib.cqvip.com/Qikan/Article/Detail?id=24254234.[131] Chen, Wenliang, Tang, Weidong, Zhang, Rujun, Lou, Liguang, Zhao, Weimin. Cytotoxic germacrane-type sesquiterpenes, pimarane-type diterpenes, and a naphthalene derivative from Wollastonia biflora. JOURNAL OF NATURAL PRODUCTS[J]. 2007, 第 4 作者70(4): 567-570, http://ir.simm.ac.cn/handle/153631/1814.[132] Mi, Y, Lou, L. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. BRITISH JOURNAL OF CANCER[J]. 2007, 97(7): 934-940, http://ir.simm.ac.cn/handle/153631/1676.[133] 米毅, 楼丽广. ZD6474逆转P-糖蛋白介导的耐药性及其机制的研究. 2007, 第 2 作者224, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD9908&filename=ZGKA200706001138&v=MDM5ODBxWTlGWmVvTUJCTkt1aGRobmo5OFRuanFxeGRFZU1PVUtyaWZaZVp2SGludFU3bkpLRm9jUHlyQWI3RzRIdGJN.[134] 米毅, 楼丽广. ZD6474诱导K562向红系分化的研究. 2007, 第 2 作者223, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD9908&filename=ZGKA200706001137&v=MTg3MDVlb01DeE5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVadkhpbnRVN25KS0ZzVFB5ckFiN0c0SHRiTXFZOUZa.[135] Ye, QingSong, Lou, LiGuang, Liu, WeiPing, Yu, Yao, Chen, XiZhu, Hou, ShuQian, Gao, WenQui, Liu, Yang. Synthesis and in vitro cytotoxicity of novel lipophilic (diamine)platinum(II) complexes of salicylate derivatives. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS[J]. 2007, 第 2 作者17(8): 2146-2149, http://dx.doi.org/10.1016/j.bmcl.2007.01.084.[136] Meng, DaHai, Xu, YongPing, Chen, WenLiang, Zou, Jian, Lou, LiGuang, Zhao, WeiMin. Anti-tumour clerodane-type diterpenes from Mitrephora thorelii. JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH[J]. 2007, 第 5 作者9(7): 679-684, http://ir.simm.ac.cn/handle/153631/1903.[137] Liu, Lunhua, Xie, Yili, Lou, Liguang. PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation. EUROPEAN JOURNAL OF CELL BIOLOGY[J]. 2006, 第 3 作者 通讯作者 85(5): 367-374, http://dx.doi.org/10.1016/j.ejcb.2005.11.005.[138] Li, LiMei, Li, GuoYou, Xiao, WeiLie, Zhou, Yan, Li, ShengHong, Huang, ShengXiong, Han, QuanBin, Ding, LiSheng, Lou, LiGuang, Sun, HanDong. A new rearranged and a new seco-ent-kaurane diterpenoids from Isodon parvifolius. TETRAHEDRON LETTERS[J]. 2006, 第 9 作者47(29): 5187-5190, http://dx.doi.org/10.1016/j.tetlet.2006.05.025.[139] Xie, Yili, Yu, Zhiguo, Liu, Lunhua, Guo, Yuewei, Lou, Liguang. Biphasic regulation of extracellular signal-regulated kinases by scalaradial, a secretory phospholipase A(2) inhibitor. CANCER BIOLOGY & THERAPY[J]. 2006, 第 5 作者 通讯作者 5(8): 988-992, http://ir.simm.ac.cn/handle/153631/1497.[140] Zhao, Yunyu, Lou, Liguang. Differential response of Akt to cyclic AMP modulates drug sensitivity. BIOLOGICAL & PHARMACEUTICAL BULLETIN[J]. 2006, 第 2 作者 通讯作者 29(7): 1331-1334, https://www.webofscience.com/wos/woscc/full-record/WOS:000239542300006.[141] 刘伦华, 楼丽广. 丝／苏氨酸蛋白激酶Akt及其靶向药物研究进展. 中国药理学通报[J]. 2006, 第 2 作者22(1): 1, http://lib.cqvip.com/Qikan/Article/Detail?id=21187337.[142] Chen, Wenliang, Tang, Weidong, Lou, Liguang, Zhao, Weimin. Pregnane, coumarin and lupane derivatives and cytotoxic constituents from Helicteres angustifolia. PHYTOCHEMISTRY[J]. 2006, 第 3 作者67(10): 1041-1047, http://dx.doi.org/10.1016/j.phytochem.2006.03.005.[143] 王猛, 唐卫东, 楼丽广, 王昕, 沈竞康. 10-羟基氮杂solamin类似物的合成及其生物活性. 中国药物化学杂志[J]. 2006, 第 3 作者16(4): 214, http://dx.doi.org/10.3969/j.issn.1005-0108.2006.04.005.[144] Zou, Jian, Mi, Yi, Chen, Wenliang, Liu, Qunfang, Wang, Jian, Lou, Liguang, Zhao, Weimin. Alkyl phloroglucinol derivatives from Syzygium levinei and their differentiation-inducing activity. PLANTA MEDICA[J]. 2006, 第 6 作者 通讯作者 72(6): 533-538, http://dx.doi.org/10.1055/s-2006-931559.[145] 刘伦华, 楼丽广. PTEN功能调节的研究进展. 中国药理学通报[J]. 2005, 第 2 作者21(7): 778, http://lib.cqvip.com/Qikan/Article/Detail?id=16165304.[146] 王玉波, 王红兵, 金慧子, 楼丽广, 秦国伟. 狼毒大戟根中二萜成分研究. 2005, 第 4 作者81-82, https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CPFD&dbname=CPFD9908&filename=ZGZO200510002034&v=MjA2NTl2SGlqbVVMN0xKbG9TUHlyUlliRzRIdFROcjQ5Rlp1c01DQk5LdWhkaG5qOThUbmpxcXhkRWVNT1VLcmlmWmVa.[147] 刘伦华, 谢一利, 楼丽广. 磷脂酰肌醇-3-激酶在胰岛素与表皮生长因子激活MAPK信号通路中的不同作用. 中国药理学通报[J]. 2005, 第 3 作者21(1): 57, http://lib.cqvip.com/Qikan/Article/Detail?id=11535917.[148] 谢一利, 楼丽广. 表皮生长因子受体信号通路及其靶向肿瘤治疗. 国外医学：肿瘤学分册[J]. 2005, 第 2 作者32(5): 361-364, http://lib.cqvip.com/Qikan/Article/Detail?id=15590153.[149] 米毅, 张建新, 李英, 楼丽广. 蛋白酶体抑制剂筛选模型的建立. 中国药理学通报[J]. 2005, 第 4 作者21(1): 123, http://lib.cqvip.com/Qikan/Article/Detail?id=11535939.[150] Liu, LH, Xie, YL, Lou, LG. Cyclic AMP inhibition of proliferation of hepatocellular carcinoma cells is mediated by Akt. CANCERBIOLOGYTHERAPY[J]. 2005, 4(11): 1240-1247, [151] 楼丽广. Cheliensisin A induction of leukemia cell apoptosis involves down-regulation of Bcl-2 expression.. 2005, 第 1 作者 通讯作者 [152] Xie, YL, Liu, LH, Huang, XC, Guo, YW, Lou, LG. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A(2). JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS[J]. 2005, 314(3): 1210-1217, [153] 赵蕴玉, 楼丽广. 肿瘤抑制因子Hamartin和Tuberin信号调控机制. 细胞生物学杂志[J]. 2005, 第 2 作者27(5): 489, http://lib.cqvip.com/Qikan/Article/Detail?id=20554064.[154] 陆长虹, 李杰, 郭伟剑, 楼丽广, 唐卫东, 郑磊贞, 章莉, 沈伟. 大黄素对乳腺癌多药耐药细胞株MCF-7／Adr的耐药逆转作用. 临床肿瘤学杂志[J]. 2004, 第 4 作者9(4): 340-343, http://lib.cqvip.com/Qikan/Article/Detail?id=10501776.[155] 钟利, 楼丽广, 胥彬. 番荔枝科植物抗癌活性成分研究的新结果. 肿瘤[J]. 2003, 第 2 作者23(2): 162-163, http://lib.cqvip.com/Qikan/Article/Detail?id=7528690.[156] 谢一利, 楼丽广. PLA2为EGF受体介导的蛋白激酶Akt磷酸化所必需. 中国药理通讯[J]. 2003, 第 2 作者20(3): 29-30, http://lib.cqvip.com/Qikan/Article/Detail?id=8531628.[157] 余伯成, 李红, 范小兵, 胡天喜, 楼丽广, 何庚华, 徐永平. 昂立品山抑瘤口服液抗小鼠肿瘤实验研究. 上海医药[J]. 2002, 第 5 作者23(7): 312-314, http://lib.cqvip.com/Qikan/Article/Detail?id=6541630.[158] 楼丽广. 小的G蛋白Rap1b介导cAMP和胰岛素刺激的持续的MAPK激活. 中国药理通讯[J]. 2002, 第 1 作者19(4): 48-48, http://lib.cqvip.com/Qikan/Article/Detail?id=7453596.[159] 马仲才, 楼丽广, 胥彬, 张周. α-双炔失碳酯体内、外抑制血管生成. 中国药理学报[J]. 2000, 第 2 作者21(10): 939, [160] 马仲才, 楼丽广, 张周, 胥彬. α-双炔失碳酯体内、外抑制血管生成（英文）. ACTA PHARMACOLOGICA SINICA[J]. 2000, 第 2 作者6, http://lib.cqvip.com/Qikan/Article/Detail?id=4000687036.[161] 楼丽广, 胥彬. 环己米特不能阻止α—双炔失碳酯诱导的白血病K562细胞凋亡. 中国药理学报[J]. 1997, 第 1 作者18(2): 169, http://lib.cqvip.com/Qikan/Article/Detail?id=2684195.[162] 楼丽广, 胥彬. 放线菌素D不能抑制α—双炔失碳酯诱导的白血病K562细胞凋亡. 中国药理学通报[J]. 1997, 第 1 作者13(3): 213-216, http://lib.cqvip.com/Qikan/Article/Detail?id=2640847.[163] 楼丽广, 胥彬. α—双炔失碳酯诱导人白血病K562细胞凋亡. 中国药理学报[J]. 1996, 第 1 作者17(3): 255, http://bjvip.las.ac.cn/qk/95561X/199603/2027054.html.[164] Zhicheng Xie, Lin Li, Yihao Guo, Mi Zhang, Taiwen Chen, Yongpeng Li, Xin Li, Xi Zhu, Yu Zhang, Liguang Lou, Youhong Hu. Discovery of novel heteroaryl alkynes for highly potent KITD816V cells inhibition to treat gastrointestinal stromal tumors. ACTA PHARMACEUTICA SINICA B. 第 10 作者http://dx.doi.org/10.1016/j.apsb.2022.07.015.
科研活动
科研项目
（1） 小分子哒嗪酮类化合物为探针研究肿瘤细胞增殖信号转导机制，主持，国家，2009-01--2011-12
（2） 云南特有香茶菜属植物中抗癌活性成分及其作用机制研究，参与，国家，2009-01--2011-12
（3） 喜诺替康原料及其制剂，参与，部委，2009-01--2010-12
（4） 新型哒嗪酮类抗肝癌候选新药研究，主持，部委，2009-01--2010-12
（5） 新长春碱类抗肿瘤药物候选物 F-XA7的临床前研究，主持，部委，2009-01--2010-12
（2） 云南特有香茶菜属植物中抗癌活性成分及其作用机制研究，参与，国家，2009-01--2011-12
（3） 喜诺替康原料及其制剂，参与，部委，2009-01--2010-12
（4） 新型哒嗪酮类抗肝癌候选新药研究，主持，部委，2009-01--2010-12
（5） 新长春碱类抗肿瘤药物候选物 F-XA7的临床前研究，主持，部委，2009-01--2010-12
指导学生
已指导学生
赵蕴玉 硕士研究生 100706-药理学
全海天 博士研究生 100706-药理学
米毅 博士研究生 100706-药理学
罗海山 博士研究生 100706-药理学
强世高 硕士研究生 100706-药理学
赵红兵 博士研究生 100706-药理学
现指导学生
孙丽萍 硕士研究生 077906-药理学
吴琼 博士研究生 100706-药理学
王蕾 博士研究生 100706-药理学
赵之欣 硕士研究生 077906-药理学
赵杰 博士研究生 100706-药理学
王泉人 博士研究生 100706-药理学